TCGA-AR-A24O-01A-11R-A169-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 120
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.560
- ANGIOGENESIS+0.550
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.550
- TGF_BETA_SIGNALING+0.550
- TNFA_SIGNALING_VIA_NFKB+0.480
- KRAS_SIGNALING_UP+0.460
- HEDGEHOG_SIGNALING+0.450
- INFLAMMATORY_RESPONSE+0.360
- PROTEIN_SECRETION+0.350
- IL6_JAK_STAT3_SIGNALING+0.330
Top 10 suppressed
- MYC_TARGETS_V2-0.610
- OXIDATIVE_PHOSPHORYLATION-0.460
- DNA_REPAIR-0.440
- MYC_TARGETS_V1-0.390
- E2F_TARGETS-0.320
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.310
- UNFOLDED_PROTEIN_RESPONSE-0.310
- MTORC1_SIGNALING-0.300
- GLYCOLYSIS-0.260
- G2M_CHECKPOINT-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CR-7376-01A-11R-2132-07 | — | — | 0.936 |
| 2 | 80cb0e05-387d-4bd8-b49c-ff2aae043982 | — | — | 0.907 |
| 3 | TCGA-85-6175-01A-11R-1820-07 | — | cohortSQ1 | 0.901 |
| 4 | TCGA-A2-A0YD-01A-11R-A109-07 | — | A | 0.901 |
| 5 | TCGA-BH-A1EO-01A-11R-A137-07 | — | A | 0.901 |
| 6 | TCGA-AC-A2B8-01A-11R-A17B-07 | — | A | 0.900 |
| 7 | 94f6e4f5-2447-4f1f-9f36-411f1c25a172 | — | — | 0.899 |
| 8 | MDT-AP-3277 | Med | Medulloblastoma | 0.897 |
| 9 | TCGA-J2-8192-01A-11R-2241-07 | — | cohortA1 | 0.889 |
| 10 | TCGA-A1-A0SD-01A-11R-A115-07 | — | A | 0.888 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.560 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.550 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.550 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.550 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.480 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.460 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.450 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.360 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.330 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.320 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.320 | Idelalisib | — uncovered |
| COMPLEMENT | 0.310 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.310 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.270 | Idelalisib | — uncovered |
| COAGULATION | 0.260 | Binimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.250 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.240 | Inavolisib | — uncovered |
| APOPTOSIS | 0.220 | Idelalisib | — uncovered |